Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · DNTH · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
32
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Dianthus Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
DNTH insider buying and selling by quarter
DNTH insider selling · DNTH insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · DNTH ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
DNTH executive sell shares · DNTH board member insider trading · DNTH insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Option | 9,375 | $207K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Sale | 5,428 | $487K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Option | 6,249 | $136K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Option | 6,908 | $124K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Sale | 16,943 | $1.54M⚡ | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Option | 3,998 | $34K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Sale | 4,159 | $380K | Form 4 |
| May 8, 2026 | Soteropoulos Paula Director | Option | 599 | $5K | Form 4 |
| May 8, 2026 | Soteropoulos Paula Director | Sale | 599 | $51K | Form 4 |
| Apr 9, 2026 | Savitz Ryan EVP, CFO & CBO | Option | 8,224 | $147K | Form 4 |
| Apr 9, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 8,224 | $739K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Option | 40,000 | $715K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 1,390 | $109K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 21,825 | $1.72M⚡ | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 1,485 | $119K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 800 | $65K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 2,366 | $196K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Option | 74,367 | $628K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 59,800 | $5.02M⚡ | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 19,469 | $1.65M⚡ | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 7,232 | $619K | Form 4 |
| Mar 31, 2026 | Soteropoulos Paula Director | Option | 599 | $5K | Form 4 |
| Mar 31, 2026 | Soteropoulos Paula Director | Sale | 599 | $48K | Form 4 |
| Mar 24, 2026 | Soteropoulos Paula Director | Option | 27,594 | $233K | Form 4 |
| Mar 24, 2026 | Soteropoulos Paula Director | Sale | 27,594 | $2.15M⚡ | Form 4 |
Randhawa Simrat
EVP, Head of R&D
Date
Jun 1
Shares
9,375
Price
$22.07
Value
$207K
Randhawa Simrat
EVP, Head of R&D
Date
Jun 1
Shares
6,249
Price
$21.77
Value
$136K
Randhawa Simrat
EVP, Head of R&D
Date
Jun 1
Shares
6,908
Price
$17.88
Value
$124K
Randhawa Simrat
EVP, Head of R&D
Date
Jun 1
Shares
16,943
Price
$90.72
Value
$1.54M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About DNTH insider trading
DNTH insider trades
Dianthus Therapeutics, Inc. (DNTH) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Randhawa Simrat (EVP, Head of R&D), Savitz Ryan (EVP, CFO & CBO), Garcia Marino (CEO AND PRESIDENT · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. DNTH insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Dianthus Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
DNTH insider trading · 5 questionsThe insiders of Dianthus Therapeutics, Inc. (DNTH) include executives and directors such as Randhawa Simrat (EVP, Head of R&D), Savitz Ryan (EVP, CFO & CBO), Garcia Marino (CEO AND PRESIDENT · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026